OBJECTIVES: Thrombocytopenia is very common after cardiac surgery, but rarely studied systematically. Heparin-induced thrombocytopenia has been studied extensively, but the diagnosis remains clouded by the lack of sensitivity and specificity of laboratory tests. It remains unknown whether a local initiative of screening program has been successful in the management of postoperative thrombocytopenia.
INTRODUCTION
Thrombocytopenia is very common after cardiac surgery, but rarely studied systematically. Heparin-induced thrombocytopenia (HIT) was described 50 years ago and has received wide attention since the late of 2000s, prompting the educational campaign to address this problem [1] . Despite clinical and laboratory evidence collected over many years, the diagnosis still remains very complex [2, 3] . The target antigen of HIT was identified in 1990s as anti-platelet factor 4 (PF4)/heparin enzyme-immune assay (Elisa) test [4] and is widely available, sensitive and simple to apply but yields frequent false-positive results. Serotonin release assay (SRA) test has better specificity but is more technically demanding and less feasible to perform. In the last several years, the concern over HIT has been no longer the under-recognition, but the overdiagnosis and over treatment. As there does not seem to have a better test in the near future, we attempted to adapt a practical solution clinically for HIT screening, prevention and treatment.
We have implemented a screening protocol to improve the management of thrombocytopenia after cardiac surgery in our busy cardiac surgery setting since 2002. The purpose of this study is to asses this decade-long screening-program through summarizing the data after isolated aortic valve surgery.
METHODS

Patient population
Our computerized Cardiovascular Surgery Division Database at Washington Hospital Center, Washington DC, was used to identify all patients coming to operation from January 2003 to 2012. To enhance the homogeneity, our study cohort included 1262 patients undergoing isolated aortic valve replacement (AVR).
The institutional review board of Medstar Research Institute approved the study protocol. All data were routinely collected.
Thrombocytopenia and PF4 antibody-enhanced screening guideline
After cardiac surgery, we monitored platelet count for all patients as baseline reference regardless of perioperative heparin or low-molecular-weight heparin (LMWH) administration. We followed the platelet count at least every other day while the patients were hospitalized during the initial 14 days after surgery. If a 50% (30% in 2003) decrease in platelet count from the highest postoperative level or an absolute count of <80 000 was identified, and there were no clear reasons to explain thrombocytopenia, anti-PF4 antibody ELISA testing (including IgG, A and M) was conducted. If the initial result was negative, but there was a strong clinical suspicion the ELISA test was repeated.
Elisa (+) is diagnosed when the patient met the thrombocytopenia screening criteria and the ELISA test was positive (OD > 0.45). Unless the patient had a known postoperative thrombosis (e.g. deep venous thromboses, pulmonary embolism, stroke), non-invasive leg studies were performed. Elisa (+) with thrombosis was diagnosed when a patient with positive ELISA had a known postoperative thrombosis or positive non-invasive leg test was positive. After surgery, neither unfractioned heparin nor LMWH was used for routine anticoagulation. When patients have mechanical valve replacement, we start aspirin 6 hours and warfarin on Day 3 after surgery; when patients have tissue valve replacement, we start aspirin on Day 1 after surgery for routine anticoagulation.
Our guideline has been considered as a primary screening protocol. We divided patients into three groups based on postoperative thrombocytopenia and Elisa test (Table 1) . Group 1 (non-thrombocytopenia group): patients did not have thrombocytopenia; Group 2 [thrombocytopenia (Elisa (−)]: patients were diagnosed with thrombocytopenia, but their Elisa test was negative; Group 3: Elisa (+) group: patients were diagnosed with thrombocytopenia and Elisa (+). Twenty-nine patients were Elisa (+) without embolithrombosis, and 14 were Elisa (+) with embolithrombosis in Group 3. Perioperative management was standardized for all patients. All the procedures were performed with cardiopulmonary bypass (CPB) and moderate hypothermia (30-32°C).
Statistical analysis
Data were tabulated as frequencies and percentages for categorical variables, and as mean and standard deviations for continuous variables. Continuous variables were compared using the Wilcoxon two-sided test and categorical variables using the χ 2 test or Fisher's exact test, as appropriate.
Multivariable logistic regression analysis was used to identify factors associated with the development of thrombocytopenia [Elisa (−)] and Elisa (+). The risk factors found to be predictive of thrombocytopenia [Elisa (−)] and Elisa (+) in univariate analysis with P < 0.15 were included into the multivariate logistic regression analysis with stepwise forward selection.
Multivariable logistic regression analysis also was constructed to define the relationship between Elisa (−) and operative outcomes. To explore the association between isolated Elisa (+) without embolithrombosis and operative mortality and postoperative bleeding, we also established a multivariable logistic regression model. Operative mortality was defined as mortality within 30 days of surgery. The models were assessed using the HosmerLemeshow test for goodness-of-fit test. A P-value of <0.05 was considered significant. Analysis was performed using the SAS statistical software (version 9.0, Cary, NC, USA).
RESULTS
Baseline characteristics
Among 1261 patients having isolated AVR surgery, 283 (22.4%) developed thrombocytopenia only [Elisa (−)]. Forty-three (3.4%) patients developed Elisa (+), 29 (2.3%) of them presented Elisa (+) without thromboembolism and 14 (1.1%) presented Elisa (+) with thromboembolism.
The baseline demographics and perioperative variables associated with thrombocytopenia and Elisa (+) in univariate analysis are summarized in Table 2 . Compared with patients testing negative for Elisa, patients testing positive were older (P < 0.01), more likely to be female, have preoperative atrial fibrillation (P = 0.01), dyslipidaemia (P = 0.013), endocarditis (P = 0.007), severe chronic pulmonary disease (P = 0.049), lower preoperative platelet count (<0.001) and more likely to receive bioprosthetic valve (P < 0.001). Patients with Elisa (+) presented a higher Society of Thoracic Surgeon (STS) mortality risk score than those without thrombocytopenia (P < 0.001). The preoperative heparin exposure including heparin treatment and cardiovascular intervention was not different. Heparin use during surgery was significantly lower in patients with Elisa (+) than those without thrombocytopenia (P = 0.001).
Operative outcomes
As reported in Table 3 , major postoperative outcomes all increased in thrombocytopenia and Elisa (+) groups. Operative mortality increased from 4.1 to 6 to 18.6% among those without thrombocytopenia, with isolated thrombocytopenia [Elisa (−)] and with Elisa (+), respectively (P < 0.001). Patients with Elisa (+) and thromboembolism had higher mortality than those with Elisa (+) only, and almost 1 in every 3 died (4 of 14 = 28.6%). The clinical outcomes were complicated by longer length of hospital stay (P < 0.001), Categorical data are presented as number (%, percentage); continuous data are presented as mean ± SD (standard deviation). ICU: intensive care unit; LOS: length of stay after surgery; ml: millilitre.
increased rate of prolonged ventilation (P < 0.001), renal failure (P < 0.001), more bleeding and more blood transfusion (P < 0.001) in patients with Elisa (+) compared without thrombocytopenia.
Risk factors influencing the development of thrombocytopenia and Elisa (+)
Covariates included in the model of thrombocytopenia [Elisa (−)] were age, gender, body mass index (BMI; categorical grouping), dyslipidaemia, preoperative endocarditis, preoperative platelet count, preoperative atrial fibrillation, preoperative steroid use, preoperative chronic pulmonary disease, preoperative cardiovascular intervention, replaced type of aortic valve and total heparin use in odds ratio (OR). After adjustment for differences in clinical risk factors through a multivariate logistic regression model (Table 4) , age, underweight BMI and severe chronic pulmonary disease were independently associated with thrombocytopenia [Elisa (−)]. Patients with preoperative higher platelet count, overweight BMI, obesity and dyslipidaemia were less likely to develop thrombocytopenia after surgery. Covariates included in the model of Elisa (+) were age, BMI, total heparin use in OR, preoperative platelet count and replaced type of aortic valve. Age (OR = 1.07, P < 0.001) and lower preoperative platelet count (OR = 0.99, P = 0.02) emerged as independent predictors for Elisa (+). Both thrombocytopenia and Elisa (+) were associated with increased mortality and bleeding (Table 5 ). Preoperative cardiovascular intervention and unfractioned heparin use during surgery were associated neither with an increased risk of thrombocytopenia [Elisa (−)] nor with Elisa (+).
AVR was done with a bioprosthetic valve in 1122 patients, and 140 received mechanical valve replacement. Two (1.4%) patients had isolated Elisa (+) without thromboembolism in mechanical valve receivers. The incidence of Elisa (+) increased to 3.7% in patients receiving a bioprosthetic valve (P = 0.22). All 14 patients had Elisa (+) with thromboembolisms were bioprosthetic valve receivers. The average age of mechanical valve receivers was 49.8 years and 70.6 in bioprosthetic valve receivers (P = 0.001).
DISCUSSION
Our screening programme provides a unique opportunity to characterize the incidences and prognostic significance of postoperative thrombocytopenia and Elisa (+) after AVR. The main findings of this study can be summarized as follows: (i) thrombocytopenia [Elisa (+) + Elisa (−)] occurred in 25.8% of patients after isolated AVR. Thrombocytopenia [Elisa (−), incidence 22.4%] was associated with increased mortality. (ii) Elisa (+) alone without thromboembolism occurred in 3.4% of patients, which is significantly lower than the reported rate of 26-53% after cardiac surgery; (iii) Elisa (+) was associated with an increased risk of mortality; (iv) age is an independent predictor of both thrombocytopenia and Elisa (+); (v) our screening programme has worked well so far based on our follow-up data.
Elisa test, HIT diagnosis, overdiagnosis and over treatment
A growing concern about the overdiagnosis and over treatment on HIT has been recently raised by numerous studies, because they reported that anti-PF4 could be detected in 26-53% of patients in the postoperative period following CPB without clinical consequences [2, [5] [6] [7] [8] , but the incidence of HIT was only between 1 and 3% after cardiac surgery [9, 10] .
The SRA test has been highly recommended as the gold standard confirmatory test for HIT [11] . However, Kawano et al. [12] reported that despite high OD values (≥1.5) in Elisa or strong positive SRA test, 3 of 5 patients did not develop HIT. Cuker reported that 91 of 100 patients were diagnosed with HIT after they were excluded by the negative SRA test over a 12-month period [1] . 
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The change from under-recognition to over diagnosis decreases the possibilities to approach an algorithm on the management of HIT effectively in the near future. This diagnostic dilemma leaves open the possibility that a primary screening protocol could be effective in screening and identifying high-risk patients, then providing opportunity for clinicians to adjust the treatments.
The screening program
Cardiac surgery patients have a likelihood of developing postoperative thrombocytopenia and HIT because of CPB and the anticoagulation with unfractioned heparin during surgery [7, 9, 10] . Since 2002, our screening protocol successfully recognized the activities of postoperative thrombocytopenia, which includes HIT and non-HIT. The review board for this program updates the thrombocytopenia screen criteria, collaborated the turning back time of the SRA test, which we sent our blood sample to a facility of Mayo Clinic, and developed practice alerts 3 months for HIT in the medical recording system. Currently, a comprehensive postoperative recognition and management protocol is available to all clinicians that involve heparin treatments in our hospital.
Clinically, Warkentin 4T's system has been highly recommended [13] [14] [15] , but several recent studies suggested that neither patients with a low score of 0-6 nor a high score of 6-8 should follow the recommended guidelines by 4T's scoring system [16, 17] . The 4T's system defines the timing of thrombocytopenia as 5-10 days after exposure to heparin or within 1 day of heparin re-exposure after 30 days of heparin exposure. It remains uncertain whether the 5-to 10-day window should apply to post-cardiac surgery patients, because cardiac surgery patients are different from other categories of patients in respect of heparin exposure. An STS guideline only indicates to collect whether patients received intravenous and/or subcutaneous heparin within 48 h preceding surgery, and it does not include one-time boluses of heparin. It is uncertain how many patients were exposed to heparin 48 h before proceeding to surgery. In our study cohort, 13.6% of patients had heparin treatment within 48 h preoperatively. If we do not count patients who had thrombocytopenia within 5 days, the incidence of Elisa (+) only would be 0.8% (10 of 1261) and of Elisa (+) with thromboembolisms would be 0.7% (7 of 1261) . By applying this screening protocol for 10 years, the incidence of Elisa (+) was 2.0% (319 of 16 528) in all surgery, and 0.9% in isolated coronary artery bypass grafting patients (100 of 11 015).
We would not disagree that there was overdiagnosis in our study, because we only tested for anti-PF4/Elisa. However, symptoms of thromboembolisms or bleeding in 14 patients were unlikely be overdiagnosed. As a primary screening program, we consider it is simple, easy to perform and effective, and it did not yield higher incidence of Elisa (+) than any other studies.
Thrombocytopenia
To date, the incidence of thrombocytopenia after cardiac surgery has been described almost exclusively in the HIT study. Our data showed that a quarter of patients had thrombocytopenia, and thrombocytopenia and Elisa (+) without thromboembolism are associated with an increased risk of postoperative mortality and bleeding. This is the first study that addresses the link between preoperative, operative characteristics and postoperative thrombocytopenia.
The impact of Elisa (+) and Elisa (+) with thromboembolisms on clinical outcomes
Previous investigators have reported that mortality was between 23.5 and 45% after different cardiac procedures [18, 19] . In our study, the 30-day mortality in patients with Elisa (+) without thromboembolism was 21.1%; it was 28.6% in Elisa (+) with thromboembolic patients. Although no significant difference was detected in postoperative outcomes between patients with Elisa (+) alone and those with thromboembolisms, the results still indicated overall worse outcomes. Our results emphasize that not only the major thromboembolic complications increased significantly, but also the whole major clinical course was complicated by Elisa (+), and Elisa (+) alone is not harmful. Because of the low incidence of Elisa (+), we were unable to determine why some patients with Elisa (+) were more likely than others to develop thromboembolic complications.
Emerging studies suggest that HIT is more than just heparin exposure [20] . In our analysis, patient age, preoperative haemoglobin, platelet count, atrial fibrillation and STS mortality risk score were found significantly different between patients with Elisa (+) and those without Elisa (+), whereas preoperative unfractioned heparin, LMWH and heparin dosage during surgery were not. We found a protective effect of higher preoperative platelet count on Elisa (+), but preoperative heparin use and the dosage of heparin did not emerge as an independent risk factor of Elisa (+). Taken together, in addition to heparin, other clinical factors play a critical role to be correlated with Elisa (+).
Study limitations
This study has limitations. First, it was a retrospective study and may include all the biases that are due to the retrospective nature. Secondly, as the Elisa (+) was not performed preoperatively, some patients might have Elisa (+) preoperatively. Thirdly, the average length of hospital stay after surgery was 6 days, and platelet drop and any possible positive Elisa (+) that occurred after discharge were missed. Thus, the rate of Elisa (+) might have been overestimated if the Elisa (+) occurred preoperatively or underestimated if the platelet count decrease and positive antibodies occurred after discharge. We speculate that this situation only happened to patients with Elisa (+) alone, and not with thromboembolisms, because institutional guideline requires a 30-day postoperative follow-up for every patient after discharge. If the patient developed thrombosis within 30 days postoperatively, the patient would be readmitted to hospitals for diagnosis and treatment. Our routine follow-up made the incidence of thromboembolisms accurate. We believe that our study is widely applicable and reflects the true world of cardiac surgery.
CONCLUSION
A very well-designed primary screening program did not increase the diagnosis of thrombocytopenia and Elisa (+). With this decade-long screening program, we found that the incidence of Elisa (+) alone and that of Elisa (+) with thromboembolisms were low after AVR. Both thrombocytopenia and Elisa (+) alone were associated with increased mortality and bleeding.
